The dosing conundrum of emicizumab: To waste product or not?
作者信息
Young Guy
机构信息
Cancer and Blood Disorders Institute, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
出版信息
Res Pract Thromb Haemost. 2023 Feb 16;7(2):100087. doi: 10.1016/j.rpth.2023.100087. eCollection 2023 Feb.
Abstract
摘要
相似文献
1
The dosing conundrum of emicizumab: To waste product or not?艾美赛珠单抗的给药难题：是否浪费药物？
Res Pract Thromb Haemost. 2023 Feb 16;7(2):100087. doi: 10.1016/j.rpth.2023.100087. eCollection 2023 Feb.
2
Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste.优化依库珠单抗-kxwh 作为血友病 A 预防治疗的维持剂量：按照产品说明书进行给药，同时尽量减少药物浪费。
J Manag Care Spec Pharm. 2023 Jan;29(1):47-57. doi: 10.18553/jmcp.2023.29.1.47.
3
The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste.艾美赛珠单抗全瓶给药的疗效：关于血浆浓度、出血和药物浪费的真实世界证据。
Res Pract Thromb Haemost. 2023 Feb 8;7(2):100074. doi: 10.1016/j.rpth.2023.100074. eCollection 2023 Feb.
4
Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.rFVIIa 与emicizumab 给药用于伴抑制物的先天性血友病 A 的安全性分析：来自 HAVEN 临床项目的经验。
J Thromb Haemost. 2019 Sep;17(9):1470-1477. doi: 10.1111/jth.14491. Epub 2019 Jun 17.
5
Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A.美国真实世界研究：培古洛单抗和艾美赛珠单抗在接受治疗的 A 型血友病患者中的应用
Expert Rev Hematol. 2022 Oct;15(10):943-950. doi: 10.1080/17474086.2022.2112171. Epub 2022 Aug 24.
6
Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis.在整个给药间隔期间，emicizumab预防出血的疗效得以维持。
Res Pract Thromb Haemost. 2023 Feb 8;7(2):100077. doi: 10.1016/j.rpth.2023.100077. eCollection 2023 Feb.
7
DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A.DosEmi 研究方案：一项四期、多中心、开放性、交叉研究，旨在评估与常规剂量依库珠单抗相比，基于药代动力学指导的降低剂量方案治疗血友病 A 患者的非劣效性。
BMJ Open. 2023 Jun 26;13(6):e072363. doi: 10.1136/bmjopen-2023-072363.
8
Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen.依库珠单抗在儿童和成人血友病 A 患者中的剂量：模拟一种方便用户使用且具有成本效益的方案。
Thromb Haemost. 2022 Feb;122(2):208-215. doi: 10.1055/a-1499-0030. Epub 2021 Jun 27.
9
Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials.重组因子VIII-Fc与艾美赛珠单抗治疗无抑制物的A型血友病患者的疗效：A-LONG和HAVEN试验的匹配调整间接比较
J Blood Med. 2021 Feb 25;12:115-122. doi: 10.2147/JBM.S288283. eCollection 2021.
10
Real-world cost estimates of initiating emicizumab in US patients with haemophilia A.美国A型血友病患者开始使用emicizumab的真实世界成本估计。
Haemophilia. 2021 Jul;27(4):591-598. doi: 10.1111/hae.14347. Epub 2021 May 29.
引用本文的文献
1
Concizumab, a Non-Replacement Therapy for Persons with Hemophilia with Inhibitors.康西珠单抗，一种用于血友病伴抑制物患者的非替代疗法。
J Clin Med. 2025 Apr 25;14(9):2961. doi: 10.3390/jcm14092961.
本文引用的文献
1
The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste.艾美赛珠单抗全瓶给药的疗效：关于血浆浓度、出血和药物浪费的真实世界证据。
Res Pract Thromb Haemost. 2023 Feb 8;7(2):100074. doi: 10.1016/j.rpth.2023.100074. eCollection 2023 Feb.
2
Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A.长达 5.8 年的依库珠单抗的长期安全性和疗效以及患者对症状和日常生活的认知：一项严重 A 型血友病患者的 1/2 期研究。
Haemophilia. 2021 Jan;27(1):81-89. doi: 10.1111/hae.14205. Epub 2020 Nov 24.
3
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.Emicizumab 在有因子 VIII 抑制剂的血友病 A 患者中的药代动力学和药效学：HAVEN 1 研究。
Thromb Haemost. 2021 Mar;121(3):351-360. doi: 10.1055/s-0040-1717114. Epub 2020 Oct 21.
4
Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.依库珠单抗对人工添加因子 VIII 的血浆标本和有抑制物的血友病 A 患者样本的 APTT、一步法及显色法检测因子 VIII 的影响。
Haemophilia. 2020 May;26(3):536-542. doi: 10.1111/hae.13990. Epub 2020 Apr 6.
5
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.皮下康西珠单抗预防治疗 A 型血友病和有抑制剂的 A/B 型血友病：2 期临床试验结果。
Blood. 2019 Nov 28;134(22):1973-1982. doi: 10.1182/blood.2019001542.
6
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.每4周给予艾美赛珠单抗预防治疗A型血友病患者的疗效、安全性及药代动力学（HAVEN 4）：一项多中心、开放标签、非随机3期研究
Lancet Haematol. 2019 Jun;6(6):e295-e305. doi: 10.1016/S2352-3026(19)30054-7. Epub 2019 Apr 16.
7
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.艾美赛珠单抗预防无抑制剂的血友病 A 患者出血。
N Engl J Med. 2018 Aug 30;379(9):811-822. doi: 10.1056/NEJMoa1803550.
8
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.依库珠单抗预防伴抑制物的血友病 A。
N Engl J Med. 2017 Aug 31;377(9):809-818. doi: 10.1056/NEJMoa1703068. Epub 2017 Jul 10.
Zotero 插件